Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months of age: a randomized controlled study
Background Due to high costs of pneumococcal conjugate vaccines (PCV), transitioning from a two (2 + 1) to a single dose (1 + 1) primary series with a booster should be considered. This study evaluated the immune response at 18 months of age following a 1 + 1 compared to a 2 + 1 schedule of 10-valen...
Saved in:
Main Authors: | Alane Izu, Eleanora Aml Mutsaerts, Courtney Olwagen, Lisa Jose, Anthonet Koen, Amit J Nana, Clare L. Cutland, Shabir A. Madhi |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2025-12-01
|
Series: | Expert Review of Vaccines |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/14760584.2025.2458179 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A population-based study on the burden of hospitalized pediatric pneumococcal disease in Taiwan before and after the introduction of 13-valent pneumococcal conjugate vaccine into the childhood immunization program in 2015
by: Ting-An Yen, et al.
Published: (2025-02-01) -
Impact of invasive and noninvasive pneumococcal diseases on adult populations: risk factors and vaccination status
by: Hasip Kahraman, et al.
Published: (2025-02-01) -
Implementation of a Targeted Technologic Screening Tool to Increase Pneumococcal Vaccine Uptake in Health-System Retail Pharmacies: A Quality Improvement Initiative
by: Annika Skogg, et al.
Published: (2024-12-01) -
Establishing a new human pneumococcal standard reference serum, MPRSS-01
by: Joseph M. Antonello, et al.
Published: (2025-01-01) -
Factors Affecting Influenza and Pneumococcal Vaccination Rates in Hemodialysis Patients: A Multicenter Study
by: Selen T, et al.
Published: (2025-01-01)